Promethera Biosciences’ mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The company is pioneering the development of cell-based therapies that provide both immunomodulatory and anti-fibrotic effects in the liver.

The company’s lead clinical program is derived from a patented allogenic liver cell platform called HepaStem. The program has the potential to target Acute-on-Chronic Liver Failure (ACLF) and other severe and more prevalent chronic liver diseases such as Non-Alcoholic Steatohepatis (NASH).

Promethera has developed its cell therapy technologies by using allogenic stem and progenitor liver cells. These are isolated, purified and expanded from healthy human livers unsuitable for transplantation. The process for developing these cells into a medical treatment enables the delivery of the cells to patients directly at point of care.

In 2018, Promethera expanded its portfolio through the acquisition of Baliapharm AG, adding a complementary therapeutic strategy focused on TNF-alpha receptor (TNF-RA1). This led to the development of Atrosimab, a novel antibody-based monovalent drug candidate currently in preclinical development for NASH and fibrosis.